"Acetates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of ACETIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxymethane structure.
| Descriptor ID |
D000085
|
| MeSH Number(s) |
D02.241.081.018 D10.251.400.045
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Acetates".
Below are MeSH descriptors whose meaning is more specific than "Acetates".
This graph shows the total number of publications written about "Acetates" by people in this website by year, and whether "Acetates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 3 | 3 |
| 1993 | 0 | 1 | 1 |
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 3 | 4 |
| 1996 | 2 | 3 | 5 |
| 1997 | 0 | 2 | 2 |
| 1998 | 3 | 2 | 5 |
| 1999 | 6 | 4 | 10 |
| 2000 | 8 | 1 | 9 |
| 2001 | 8 | 3 | 11 |
| 2002 | 43 | 22 | 65 |
| 2003 | 34 | 19 | 53 |
| 2004 | 35 | 29 | 64 |
| 2005 | 27 | 28 | 55 |
| 2006 | 31 | 28 | 59 |
| 2007 | 30 | 25 | 55 |
| 2008 | 45 | 38 | 83 |
| 2009 | 45 | 35 | 80 |
| 2010 | 62 | 36 | 98 |
| 2011 | 45 | 43 | 88 |
| 2012 | 48 | 39 | 87 |
| 2013 | 52 | 47 | 99 |
| 2014 | 53 | 40 | 93 |
| 2015 | 41 | 30 | 71 |
| 2016 | 50 | 46 | 96 |
| 2017 | 44 | 34 | 78 |
| 2018 | 43 | 46 | 89 |
| 2019 | 21 | 19 | 40 |
| 2020 | 2 | 4 | 6 |
| 2021 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Acetates" by people in Profiles.
-
Montelukast and Coronavirus Disease 2019: A Scoping Review. Iran J Allergy Asthma Immunol. 2021 Aug 07; 20(4):384-393.
-
Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity. Eur J Pharmacol. 2021 Aug 05; 904:174196.
-
Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study. Pharmacol Rep. 2021 Jun; 73(3):926-938.
-
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Int J Infect Dis. 2021 Apr; 105:598-605.
-
Leukotrienes, a potential target for Covid-19. Prostaglandins Leukot Essent Fatty Acids. 2020 10; 161:102174.
-
Montelukast's ability to fight COVID-19 infection. J Asthma. 2021 10; 58(10):1348-1349.
-
Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. Drug Discov Today. 2020 12; 25(12):2076-2079.
-
Montelukast in children with allergic rhinitis amid COVID-19 pandemic. Acta Paediatr. 2020 10; 109(10):2151.